Review
Year 2018,
Volume: 3 Issue: 2, 56 - 58, 09.10.2018
Abstract
Bowen hastalığı(BH) ilk olarak
1912 yılında intraepitelyal(in situ) skuamöz hücreli karsinom(SHK) olarak
tanımlanmıştır. Histopatolojide epidermiste tam kat epitelyal atipi ile
karakterizedir. Etyolojik nedenler arasında UV maruziyeti en önemli etkendir. Yaşla birlikte görülme sıklığı
artar , pik insidansa 7. dekatta ulaşır ve kadınlarda biraz daha sık gözlenir.
BH'nın % 3–5 oranında invaziv karsinom riski mevcuttur, bu oran perianal bölgede
%10'dur. Tedavi seçimine lezyonun büyüklüğü, kalınlığı, lezyonun yerleşim yeri
hastanın yaşı ve ekonomik maliyetler göz önünde bulundurularak karar verilir.
Keywords
References
- Referans 1. Morton CA, Birnie AJ, Eedy DJ. British Association of Dermatologists’ guidelines for the management of squamous cell carcinoma in situ (Bowen’sdisease). Br J Dermatol 2014;170:245-60.
- Referans 2. Foo CC, Lee JS, Guilanno V et al. Squamous cell carcinoma and Bowen’s disease of the skin in Singapore. AnnAcadMedSingapore 2007; 36:189–93.
- Referans 3. Karaarslan I. Aktinik Keratoz, Bowen Hastalığı ve Skuamöz Hücreli Karsinomlarda Dermoskopi. Turk J Dermatol 2016;10:32-7.
- Referans 4. Yavuz İH, YavuzÖG, Cevit R ve ark. Gecikmiş Bir Tanı:Bowen Hastalığı. Dermatoz 2015;6:1-3
- Referans 5. Truchuelo MT, Perez B, Fernandez-GuarinoM, et all.Fluorescence diagnosis and photodynamic therapyfor Bowen’s disease treatment. J EurAcadDermatolVenerol 2014;28:86-93.
- Referans 6. Lee JH, BaeJM, KimGM. Successful treatment of Bowen’s disease with ingenol mebutate 0.05% gel. JDermatol2015;42:920-1
- Referans 7. KoDY, KimKH, Song KH. A randomized trial comparing methylaminolaevulinate photodynamic therapy with and without Er:YAG ablative fractional laser treatment in Asian patients with lower extremity Bowen disease: results from a 12-month follow-up. Br J Dermatol 2014;170:165-72.
Year 2018,
Volume: 3 Issue: 2, 56 - 58, 09.10.2018
Abstract
References
- Referans 1. Morton CA, Birnie AJ, Eedy DJ. British Association of Dermatologists’ guidelines for the management of squamous cell carcinoma in situ (Bowen’sdisease). Br J Dermatol 2014;170:245-60.
- Referans 2. Foo CC, Lee JS, Guilanno V et al. Squamous cell carcinoma and Bowen’s disease of the skin in Singapore. AnnAcadMedSingapore 2007; 36:189–93.
- Referans 3. Karaarslan I. Aktinik Keratoz, Bowen Hastalığı ve Skuamöz Hücreli Karsinomlarda Dermoskopi. Turk J Dermatol 2016;10:32-7.
- Referans 4. Yavuz İH, YavuzÖG, Cevit R ve ark. Gecikmiş Bir Tanı:Bowen Hastalığı. Dermatoz 2015;6:1-3
- Referans 5. Truchuelo MT, Perez B, Fernandez-GuarinoM, et all.Fluorescence diagnosis and photodynamic therapyfor Bowen’s disease treatment. J EurAcadDermatolVenerol 2014;28:86-93.
- Referans 6. Lee JH, BaeJM, KimGM. Successful treatment of Bowen’s disease with ingenol mebutate 0.05% gel. JDermatol2015;42:920-1
- Referans 7. KoDY, KimKH, Song KH. A randomized trial comparing methylaminolaevulinate photodynamic therapy with and without Er:YAG ablative fractional laser treatment in Asian patients with lower extremity Bowen disease: results from a 12-month follow-up. Br J Dermatol 2014;170:165-72.
There are 7 citations in total.
Details
| Primary Language | Turkish |
|---|---|
| Journal Section | Kısa Derlemeler |
| Authors | |
| Publication Date | October 9, 2018 |
| Published in Issue | Year 2018 Volume: 3 Issue: 2 |